Literature DB >> 26727632

Poly(glycoamidoamine) Brushes Formulated Nanomaterials for Systemic siRNA and mRNA Delivery in Vivo.

Yizhou Dong1,2, J Robert Dorkin, Weiheng Wang1,2, Philip H Chang1,2, Matthew J Webber1,2, Benjamin C Tang1,2, Junghoon Yang1, Inbal Abutbul-Ionita3, Dganit Danino3, Frank DeRosa4, Michael Heartlein4, Robert Langer1,2, Daniel G Anderson1,2.   

Abstract

Safe and effective delivery is required for siRNA and mRNA-based therapeutics to reach their potential. Here, we report on the development of poly(glycoamidoamine) brush nanoparticles as delivery vehicles for siRNA and mRNA. These polymers were capable of significant delivery of siRNA against FVII and mRNA-encoding erythropoietin (EPO) in mice. Importantly, these nanoparticles were well-tolerated at their effective dose based on analysis of tissue histology, systemic cytokine levels, and liver enzyme chemistry. The polymer brush nanoparticles reported here are promising for therapeutic applications.

Entities:  

Keywords:  erythropoietin; mRNA; nanomaterial; polymer brush; siRNA

Mesh：

Substances：

Year:  2016        PMID： 26727632      PMCID： PMC5278877          DOI： 10.1021/acs.nanolett.5b02428

Source DB:  PubMed          Journal:  Nano Lett        ISSN： 1530-6984            Impact factor:   11.189


  36 in total

1.  Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction.

Authors:  Lior Zangi; Kathy O Lui; Alexander von Gise; Qing Ma; Wataru Ebina; Leon M Ptaszek; Daniela Später; Huansheng Xu; Mohammadsharif Tabebordbar; Rostic Gorbatov; Brena Sena; Matthias Nahrendorf; David M Briscoe; Ronald A Li; Amy J Wagers; Derrick J Rossi; William T Pu; Kenneth R Chien
Journal:  Nat Biotechnol       Date:  2013-09-08       Impact factor: 54.908

Review 2.  Safety profile of RNAi nanomedicines.

Authors:  Scott A Barros; Jared A Gollob
Journal:  Adv Drug Deliv Rev       Date:  2012-06-22       Impact factor: 15.470

3.  Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates.

Authors:  Yizhou Dong; Kevin T Love; J Robert Dorkin; Sasilada Sirirungruang; Yunlong Zhang; Delai Chen; Roman L Bogorad; Hao Yin; Yi Chen; Arturo J Vegas; Christopher A Alabi; Gaurav Sahay; Karsten T Olejnik; Weiheng Wang; Avi Schroeder; Abigail K R Lytton-Jean; Daniel J Siegwart; Akin Akinc; Carmen Barnes; Scott A Barros; Mary Carioto; Kevin Fitzgerald; Julia Hettinger; Varun Kumar; Tatiana I Novobrantseva; June Qin; William Querbes; Victor Koteliansky; Robert Langer; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

4.  In vivo delivery of nucleic acids via glycopolymer vehicles affords therapeutic infarct size reduction in vivo.

Authors:  Michael Tranter; Yemin Liu; Suiwen He; James Gulick; Xiaoping Ren; Jeffrey Robbins; W Keith Jones; Theresa M Reineke
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

5.  Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

Authors:  Michael S D Kormann; Günther Hasenpusch; Manish K Aneja; Gabriela Nica; Andreas W Flemmer; Susanne Herber-Jonat; Marceline Huppmann; Lauren E Mays; Marta Illenyi; Andrea Schams; Matthias Griese; Iris Bittmann; Rupert Handgretinger; Dominik Hartl; Joseph Rosenecker; Carsten Rudolph
Journal:  Nat Biotechnol       Date:  2011-01-09       Impact factor: 54.908

6.  In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight.

Authors:  James E Dahlman; Carmen Barnes; Omar Khan; Aude Thiriot; Siddharth Jhunjunwala; Taylor E Shaw; Yiping Xing; Hendrik B Sager; Gaurav Sahay; Lauren Speciner; Andrew Bader; Roman L Bogorad; Hao Yin; Tim Racie; Yizhou Dong; Shan Jiang; Danielle Seedorf; Apeksha Dave; Kamaljeet S Sandu; Matthew J Webber; Tatiana Novobrantseva; Vera M Ruda; Abigail K R Lytton-Jean; Christopher G Levins; Brian Kalish; Dayna K Mudge; Mario Perez; Ludmila Abezgauz; Partha Dutta; Lynelle Smith; Klaus Charisse; Mark W Kieran; Kevin Fitzgerald; Matthias Nahrendorf; Dganit Danino; Rubin M Tuder; Ulrich H von Andrian; Akin Akinc; Avi Schroeder; Dipak Panigrahy; Victor Kotelianski; Robert Langer; Daniel G Anderson
Journal:  Nat Nanotechnol       Date:  2014-05-11       Impact factor: 39.213

7.  mRNA is an endogenous ligand for Toll-like receptor 3.

Authors:  Katalin Karikó; Houping Ni; John Capodici; Marc Lamphier; Drew Weissman
Journal:  J Biol Chem       Date:  2004-01-16       Impact factor: 5.157

Review 8.  Vaccination with messenger RNA (mRNA).

Authors:  Steve Pascolo
Journal:  Handb Exp Pharmacol       Date:  2008

9.  Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format.

Authors:  Kyle K L Phua; Kam W Leong; Smita K Nair
Journal:  J Control Release       Date:  2013-01-07       Impact factor: 9.776

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694
View more
  34 in total

Review 1.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.

Authors:  Piotr S Kowalski; Arnab Rudra; Lei Miao; Daniel G Anderson
Journal:  Mol Ther       Date:  2019-02-19       Impact factor: 11.454

Review 2.  Using macropinocytosis for intracellular delivery of therapeutic nucleic acids to tumour cells.

Authors:  Arpan S Desai; Morag R Hunter; Alexander N Kapustin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-04       Impact factor: 6.237

3.  Preparation and Optimization of Lipid-Like Nanoparticles for mRNA Delivery.

Authors:  Bin Li; Yizhou Dong
Journal:  Methods Mol Biol       Date:  2017

Review 4.  Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.

Authors:  S Guan; J Rosenecker
Journal:  Gene Ther       Date:  2017-01-17       Impact factor: 5.250

5.  A Potent Branched-Tail Lipid Nanoparticle Enables Multiplexed mRNA Delivery and Gene Editing In Vivo.

Authors:  Khalid A Hajj; Jilian R Melamed; Namit Chaudhary; Nicholas G Lamson; Rebecca L Ball; Saigopalakrishna S Yerneni; Kathryn A Whitehead
Journal:  Nano Lett       Date:  2020-06-09       Impact factor: 11.189

6.  Poly(glycoamidoamine) brush nanomaterials for systemic siRNA delivery in vivo.

Authors:  X Luo; W Wang; J R Dorkin; O Veiseh; P H Chang; I Abutbul-Ionita; D Danino; R Langer; D G Anderson; Y Dong
Journal:  Biomater Sci       Date:  2016-12-20       Impact factor: 6.843

7.  Lipidoid-siRNA Nanoparticle-Mediated IL-1β Gene Silencing for Systemic Arthritis Therapy in a Mouse Model.

Authors:  Ping Song; Chuanxu Yang; Jesper Skovhus Thomsen; Frederik Dagnæs-Hansen; Maria Jakobsen; Annemarie Brüel; Bent Deleuran; Jørgen Kjems
Journal:  Mol Ther       Date:  2019-05-15       Impact factor: 11.454

8.  Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA.

Authors:  Jason B Miller; Shuyuan Zhang; Petra Kos; Hu Xiong; Kejin Zhou; Sofya S Perelman; Hao Zhu; Daniel J Siegwart
Journal:  Angew Chem Int Ed Engl       Date:  2016-12-16       Impact factor: 15.336

9.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

Review 10.  Nanoscale platforms for messenger RNA delivery.

Authors:  Bin Li; Xinfu Zhang; Yizhou Dong
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.